An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Acronyms ASPIRE
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 10 Sep 2019 Status changed from active, no longer recruiting to completed.
- 22 Mar 2019 This trial was completed in Hungary (end date: 2018-12-06), according to European Clinical Trials Database.
- 03 Mar 2019 This trial was completed in Estonia (end date: 2018-12-06), according to European Clinical Trials Database.